Health Care & Life Sciences » Biotechnology | Audentes Therapeutics Inc.

Audentes Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
3.00
35.00
302.00
1,736.00
3,398.00
5,595
Gross Income
3.00
35.00
302.00
1,736.00
3,398.00
5,595
SG&A Expense
3,051.00
10,915.00
25,893.00
58,208.00
89,516.00
131,075
EBIT
3,054.00
10,950.00
26,195.00
59,944.00
92,914.00
136,670
Unusual Expense
-
-
531.00
102.00
263.00
2,298
Non Operating Income/Expense
-
125.00
23.00
94.00
74.00
479
Pretax Income
3,054.00
10,819.00
26,458.00
59,668.00
92,484.00
128,821
Income Tax
-
-
-
-
2,246.00
-
Consolidated Net Income
3,054.00
10,819.00
26,458.00
59,668.00
90,238.00
128,821
Net Income
3,054.00
10,819.00
26,458.00
59,668.00
90,238.00
128,821
Net Income After Extraordinaries
3,054.00
10,819.00
26,458.00
59,668.00
90,238.00
128,821
Net Income Available to Common
3,054.00
10,819.00
26,458.00
59,668.00
90,238.00
128,821
EPS (Basic)
4.59
9.67
10.33
5.59
3.40
3.40
Basic Shares Outstanding
664.90
1,118.70
2,561.60
10,673.60
26,578.20
37,839.90
EPS (Diluted)
4.59
9.67
10.33
5.59
3.40
3.40
Diluted Shares Outstanding
664.90
1,118.70
2,561.60
10,673.60
26,578.20
37,839.90
EBITDA
3,051.00
10,915.00
25,893.00
58,208.00
89,516.00
131,075
Non-Operating Interest Income
-
6.00
245.00
472.00
767.00
6,030

About Audentes Therapeutics

View Profile
Address
600 California Street
San Francisco California 94108
United States
Employees -
Website http://www.audentestx.com
Updated 07/08/2019
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.